ABERA BIOSCIENCE AB Cash Flow Conversion Efficiency
ABERA BIOSCIENCE AB cash flow conversion efficiency. Based on the latest financial reports, ABERA BIOSCIENCE AB (8WK) has a cash flow conversion efficiency ratio of -0.317x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-7.44 Million ≈ $-8.70 Million USD) by net assets (€23.48 Million ≈ $27.46 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of ABERA BIOSCIENCE AB (2022–2025)
Cash flow conversion efficiency of ABERA BIOSCIENCE AB from 2022 to 2025. This chart illustrates how ABERA BIOSCIENCE AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest ABERA BIOSCIENCE AB stock price today for real-time trading data and today's change.
ABERA BIOSCIENCE AB Cash Flow Conversion Ratio Explained
ABERA BIOSCIENCE AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
ABERA BIOSCIENCE AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ABERA BIOSCIENCE AB ranked by their cash flow conversion efficiency. Also see how much is ABERA BIOSCIENCE AB worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Inocycle Technology Tbk PT
JK:INOV
|
0.029x |
|
INCREDIBLE INDUSTRIES LIMITED
NSE:INCREDIBLE
|
0.022x |
|
IntegraFin Holdings plc
LSE:IHP
|
1.676x |
|
RN2 Technologies Co. Ltd
KQ:148250
|
0.001x |
|
Taiwan Thick-Film Ind
TWO:6246
|
0.120x |
|
Pelikan International Corp
KLSE:5231
|
-0.039x |
|
Neurosense Therapeutics Ltd
NASDAQ:NRSN
|
1.177x |
|
FIREBIRD METALS LTD
F:7Y2
|
N/A |
Annual Cash Flow Conversion Efficiency for ABERA BIOSCIENCE AB (2022–2025)
The table below shows the annual cash flow conversion efficiency of ABERA BIOSCIENCE AB from 2022 to 2025. Review ABERA BIOSCIENCE AB (8WK) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €19.29 Million ≈ $22.55 Million |
€-3.26 Million ≈ $-3.81 Million |
-0.169x | -638.52% |
| 2024-12-31 | €8.66 Million ≈ $10.12 Million |
€-198.00K ≈ $-231.48K |
-0.023x | +99.27% |
| 2023-12-31 | €5.66 Million ≈ $6.61 Million |
€-17.71 Million ≈ $-20.71 Million |
-3.132x | -166.86% |
| 2022-12-31 | €16.78 Million ≈ $19.62 Million |
€-19.69 Million ≈ $-23.02 Million |
-1.174x | -- |
About ABERA BIOSCIENCE AB
Abera Bioscience AB, a platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally. The company's development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead va… Read more